On Thursday, Constellation Software reported its Q3, 2017 results. The company earned $54.26-million on revenue of $637.0-million, a 17 per cent topline bump over the $546.0-million it posted in last year’s third quarter.
Abernethy notes that the numbers came in below his estimates of $173.0-million in EBITDA, but the company’s revenue number topped his expectation of $626.0-million.
In a research update to clients today, Abernethy maintained his “Hold” rating and one-year price target of $680.00 on Constellation Software, implying a return of -8.1 per cent at the time of publication. The analyst explained his reasoning.
“Post Q3, we are marginally increasing our revenue estimates, decreasing our EBITDA estimates, and increasing our tax assumptions,” he said. “We are rolling our valuation forward to 2019E and our C$680 target price remains unchanged based on a blended approach, which includes P/E multiples, EV/FCF, EV/Recurring Maintenance revenue, and our DCF. In our view, CSU continues to trade at a relatively rich ~7.5x forward EV/Recurring revenue on 2018E. We believe Constellation still has the opportunity to drive material revenue growth and steadily scale its operations over the next five years. However, at current stock price levels, we are maintaining our Hold rating.”
Abernethy thinks Constellation will generate EBITDA of $641.1-million on revenue of $2.46-billion in fiscal 2017. He expects those numbers will improve to EBITDA of $731.9-million on a topline of $2.80-billion the following year.
Haywood Securities analyst Neal Gilmer says lower Canadian cannabis market share is weighing on Tilray Brands (Tilray Brands Stock Quote,… [Read More]
National Bank Financial analyst Baltej Sidhu says Anaergia’s (Anaergia Stock Quote, Chart, News, Analysts, Financials TSX:ANRG) divestiture of two legacy… [Read More]
RBC assistant chief economist Cynthia Leach says the public sector is playing a larger role in Canada’s investment boom than… [Read More]
Research Capital analyst Andre Uddin says Eupraxia Pharmaceuticals (Eupraxia Pharmaceuticals Stock Quote, Chart, News, Analysts, Financials TSX:EPRX) reported another strong… [Read More]
Roth Capital Partners analyst Craig Irwin says VersaBank (VersaBank Stock Quote, Chart, News, Analysts, Financials NASDAQ:VBNK) is nearing a potential… [Read More]
Roth Capital Partners analyst Max Masucci says Rapid Micro Biosystems (Rapid Micro Biosystems Stock Quote, Chart, News, Analysts, Financials NASDAQ:RPID)… [Read More]